Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MediPal Holdings Corporation (7459.T)
Tokyo, JP
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including medical equipment, materials, and clinical diagnostic reagents, utilized across diagnostics, testing, treatment, and administration, often from the pre-symptomatic stage. It also offers contract-based post-marketing surveillance (PMS) services to manufacturers and strategically invests in products like orphan drugs. Beyond pharmaceuticals, Medipal Holdings diversifies its wholesale activities to encompass cosmetics, daily necessities, and over-the-counter medications. Its extensive product portfolio further includes animal health products for companion animals, raw materials for food processing in the agricultural, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. The company also provides a comprehensive suite of specialized services. These include conducting contract epidemiological and clinical studies, creating computerized databases for medical supplies and master product data for healthcare facilities, and offering health insurance claims reviews, medical coding dispatch, outsourcing, and remote education. Medipal's operations extend to life and non-life insurance agency services, cleaning management, the full management and operation of distribution centers, commissioned delivery, and worker dispatch. Additionally, it handles the planning, management, administration, and product/service development for its branded Class A health dispensing pharmacies. Serving an expansive client base, Medipal Holdings partners with hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company adopted its current name, Medipal Holdings Corporation in October 2009, having previously operated as Mediceo Paltac Holdings Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +1.79% | +0.48% | -2.83% | +7.68% | +1.04% | +22.57% | +26.41% | +35.59% | +47.90% | +208.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+4.0% Q1'26: +4.8% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+7.0% ★ Q1'26: +29.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.4% Q1'26: +1.1% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+6.8% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-1.3% ★ Q1'26: -2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 4 EPS Ana. |
Mar 2027 3 Rev. Ana. 1 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.87T
est: 2.89T (-0.5%)
|
3.03T
est: 3.03T (-0.2%)
|
3.06T
est: 3.08T (-0.5%)
|
3.15T
est: 3.14T (+0.3%)
|
3.18T
est: 3.18T (+0.0%)
|
3.25T
est: 3.25T (+0.2%)
|
3.21T
est: 3.19T (+0.5%)
|
3.29T
est: 3.31T (-0.4%)
|
3.36T
est: 3.35T (+0.4%)
|
3.56T
est: 3.58T (-0.6%)
|
3.67T
est: 3.66T (+0.2%)
|
3.80T
3.79T – 3.81T
+3.8% YoY
|
3.87T
3.87T – 3.88T
+1.9% YoY
|
3.99T
3.92T – 4.05T
+3.0% YoY
|
4.04T
4.01T – 4.06T
+1.1% YoY
|
4.19T
4.15T – 4.22T
+3.8% YoY
|
| EBITDA |
45.12B
est: 68.71B (-34.3%)
|
54.58B
est: 72.17B (-24.4%)
|
53.05B
est: 73.22B (-27.5%)
|
59.64B
est: 74.60B (-20.1%)
|
63.40B
est: 75.67B (-16.2%)
|
67.80B
est: 77.23B (-12.2%)
|
53.37B
est: 75.97B (-29.8%)
|
59.96B
est: 78.61B (-23.7%)
|
63.62B
est: 79.62B (-20.1%)
|
65.31B
est: 69.47B (-6.0%)
|
74.03B
est: 71.09B (+4.1%)
|
73.77B
73.50B – 73.91B
+3.8% YoY
|
75.15B
75.05B – 75.26B
+1.9% YoY
|
77.40B
76.03B – 78.47B
+3.0% YoY
|
78.28B
77.82B – 78.73B
+1.1% YoY
|
81.22B
80.44B – 81.85B
+3.8% YoY
|
| EBIT |
32.80B
est: 55.19B (-40.6%)
|
42.13B
est: 57.97B (-27.3%)
|
39.26B
est: 58.82B (-33.2%)
|
44.26B
est: 59.93B (-26.1%)
|
49.47B
est: 60.78B (-18.6%)
|
53.11B
est: 62.04B (-14.4%)
|
38.58B
est: 61.03B (-36.8%)
|
45.63B
est: 63.15B (-27.7%)
|
48.97B
est: 63.96B (-23.4%)
|
47.33B
est: 50.72B (-6.7%)
|
55.61B
est: 51.91B (+7.1%)
|
53.86B
53.67B – 53.97B
+3.8% YoY
|
54.87B
54.80B – 54.95B
+1.9% YoY
|
56.52B
55.52B – 57.29B
+3.0% YoY
|
57.15B
56.82B – 57.48B
+1.1% YoY
|
59.31B
58.74B – 59.76B
+3.8% YoY
|
| Net Income |
23.69B
est: 18.61B (+27.3%)
|
30.77B
est: 25.88B (+18.9%)
|
29.01B
est: 26.89B (+7.9%)
|
34.78B
est: 32.17B (+8.1%)
|
34.36B
est: 31.83B (+8.0%)
|
37.97B
est: 35.72B (+6.3%)
|
23.93B
est: 21.20B (+12.9%)
|
29.42B
est: 33.88B (-13.2%)
|
38.81B
est: 33.71B (+15.1%)
|
41.48B
est: 38.32B (+8.2%)
|
40.28B
est: 43.67B (-7.8%)
|
41.34B
37.80B – 45.18B
-5.3% YoY
|
38.05B
37.62B – 38.48B
-8.0% YoY
|
39.78B
34.55B – 44.37B
+4.5% YoY
|
41.85B
41.45B – 42.26B
+5.2% YoY
|
44.19B
43.63B – 44.63B
+5.6% YoY
|
| SGA |
158.35B
est: 119.06B (+33.0%)
|
164.57B
est: 125.06B (+31.6%)
|
167.85B
est: 126.87B (+32.3%)
|
170.58B
est: 129.28B (+32.0%)
|
171.15B
est: 131.12B (+30.5%)
|
171.02B
est: 133.82B (+27.8%)
|
162.80B
est: 131.65B (+23.7%)
|
159.38B
est: 136.22B (+17.0%)
|
163.04B
est: 137.97B (+18.2%)
|
185.68B
est: 179.67B (+3.3%)
|
186.63B
est: 183.86B (+1.5%)
|
190.78B
190.08B – 191.16B
+3.8% YoY
|
194.36B
194.11B – 194.65B
+1.9% YoY
|
200.19B
196.64B – 202.94B
+3.0% YoY
|
202.44B
201.28B – 203.61B
+1.1% YoY
|
210.07B
208.05B – 211.68B
+3.8% YoY
|
| EPS |
104.72
est: 89.27 (+17.3%)
|
135.89
est: 124.12 (+9.5%)
|
128.12
est: 128.99 (-0.7%)
|
154.13
est: 154.29 (-0.1%)
|
154.08
est: 152.65 (+0.9%)
|
175.80
est: 171.32 (+2.6%)
|
113.95
est: 101.66 (+12.1%)
|
140.13
est: 162.50 (-13.8%)
|
184.82
est: 161.69 (+14.3%)
|
195.83
est: 186.44 (+5.0%)
|
193.19
est: 212.45 (-9.1%)
|
200.50
183.67 – 219.53
-5.6% YoY
|
185.11
182.80 – 186.96
-7.7% YoY
|
199.22
167.88 – 215.60
+7.6% YoY
|
203.37
201.40 – 205.33
+2.1% YoY
|
214.70
212.02 – 216.84
+5.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kuniaki Imagawa | Deputy Head of Pharmaceutical Business & Director | — | male |
| Shinjiro Watanabe | GM of Information Systems Management Division & Director | — | male |
| Shuichi Watanabe | Chief Compliance Officer, Chief Executive Officer, President & Representative Director | — | male |
| Toshihide Yoda | Senior MD of Investor Relations, GM of Business Development Department & Director | — | male |
| Toshiyuki Ikeuchi | Executive Officer & Head of Corporate Communications Department, Corporate Planning Division | — | — |
| Yasuhiro Choufuku | Executive Vice President & Representative Director | — | male |
| Yuji Sakon | MD, GM of Administration Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7459.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
